论文部分内容阅读
Glatiramer acetate(GA)是一种人工新合成的肽类制剂,由四种氨基酸组成。实验研究表明它对人类多发性硬化(MS)的动物模型,即实验性自身免疫性脑脊髓炎(EAE)有防治作用。GA对MS的临床前及临床Ⅰ期、Ⅱ期、Ⅲ期试验均表明也有治疗作用,虽还没有治愈MS的病例报道,但它能降低复发率及减轻病残,尤其对复发缓解型MS(RRMS)更有效。核磁共振(MRI)增强后显示病灶明显减少,这也支持上述观点。使用GA副作用小,病人可以耐受,有可能替代IFN-β。因此,GA可成为治疗MS的一线药。今后应扩大GA的试验范围(如用于治疗PPMS)及给药途径,进一步研究GA的临床应用价值。
Glatiramer acetate (GA) is a synthetic, artificial peptide that consists of four amino acids. Experimental studies have shown that it has a preventive and therapeutic effect on animal models of human multiple sclerosis (MS), experimental autoimmune encephalomyelitis (EAE). GA on MS preclinical and clinical phase Ⅰ, Ⅱ, Ⅲ trials have shown that there are therapeutic effects, although no cases of MS have been reported, but it can reduce the recurrence rate and reduce disability, especially for relapsing-remitting MS ( RRMS) is more effective. Increased nuclear magnetic resonance (MRI) showed a significant reduction in lesions, which also supports this view. With GA, side effects are small and patients are tolerant and may replace IFN-β. Therefore, GA can be the first line of treatment for MS. Future GA should expand the scope of the trial (such as for the treatment of PPMS) and route of administration, further study of the clinical value of GA.